Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma (Q33711287)

28 July 2017

title

Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma (English)

1 reference

esophageal squamous cell carcinoma

28 July 2017

0 references

1 reference

1 reference

Yongshun Chen

1

1 reference

28 July 2017

Xiaoyuan Wu

2

1 reference

28 July 2017

Shanshan Bu

3

1 reference

28 July 2017

Chunyu He

4

1 reference

28 July 2017

Wen Wang

5

1 reference

28 July 2017

Jinsong Liu

6

1 reference

28 July 2017

Wei Guo

7

1 reference

28 July 2017

Bo Tan

8

1 reference

28 July 2017

Yanxia Wang

9

1 reference

28 July 2017

Jianhua Wang

10

1 reference

28 July 2017

publication date

14 September 2012

1 reference

28 July 2017

1 reference

28 July 2017

volume

103

1 reference

28 July 2017

issue

11

1 reference

28 July 2017

page(s)

1979-1984

1 reference

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

21 June 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

21 June 2018

Cancer trends in China

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Multimodality treatment of esophageal cancer: a review of the current status and future directions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Targeted therapies for esophageal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

EGFR and cancer prognosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439109

Definitive Chemoradiation for Oesophageal Cancer — a Standard of Care in Patients with Non-metastatic Oesophageal Cancer

30 October 2018

1 reference

12 December 2020

EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus

1 reference

12 December 2020

Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus

1 reference

12 December 2020

Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity

1 reference

12 December 2020

Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma

1 reference

12 December 2020

Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group

1 reference

12 December 2020

INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy

1 reference

12 December 2020

10.1111/J.1349-7006.2012.02393.X

Identifiers

DOI

1 reference

28 July 2017

1 reference

28 July 2017

1 reference